No clinically important drug interactions have been identified in clinical trials of desloratidine. Erythromycin and ketoconazole - although these drugs inhibit the metabolism of loratidine , no adverse clinical effects have been noted.

Allergic Rhinitis

Antihistamines Include: First Generation ( Non-selective ) Ethanolamine- Carbinoxamine. Clemastine, Diphenhydramine. Ethylenediamines- Pyrilamine, Triplennamine Akylamines- Brompheneramine, Chlorpheniramine, Dexchlor pheniramine,Pheniramine,Triprolidine Phenothiazines- Methidilazine, Promethizine, trimeprazine  Piperidines- Azatadine, Cyproheptadine, Phenindamine Miscellaneous- Astemazole, Loratadine, Terfenadine Second Generation ( Peripherally selective ) Phthalazinone - Azelastine Piperazine - Cetrizine Refer - Chlorpheniramine maleate

Headache, dry mouth and fatigue.

Hypersensitivity to desloratidine or to loratidine.

Special precautions: It should not be used in pregnancy unless the potential benefits outweigh the risks. As desloratidine is excreted into breast milk, it is not recommended for use in breastfeeding women.

Desloratidine should be used with caution in patients with severe renal impairment.

Antihistamines Include: First Generation ( Non-selective ) Ethanolamine- Carbinoxamine. Clemastine, Diphenhydramine. Ethylenediamines- Pyrilamine, Triplennamine Akylamines- Brompheneramine, Chlorpheniramine, Dexchlor pheniramine,Pheniramine,Triprolidine Phenothiazines- Methidilazine, Promethizine, trimeprazine  Piperidines- Azatadine, Cyproheptadine, Phenindamine Miscellaneous- Astemazole, Loratadine, Terfenadine Second Generation ( Peripherally selective ) Phthalazinone - Azelastine Piperazine - Cetrizine Refer - Chlorpheniramine maleate

Pharmacology:

Desloratidine is a long-acting, non-sedating, selective peripheral hisrtamine H2 receptor antagonist. It is the major active metabolite of the parent drug loratidine. Desloratidine acts by inhibiting the release of pro-inflammatory mediators from human mast cells/basophils

Pharmacokinetics:

Desloratidine is well absorbed with maximum plasma concentrations within about 3 hours; the terminal elimination half-life is approximately 27 hours Food does not affect the extent of absorption. Desloratidine is primarily metabolised by hydroxylation and excreted mainly in the urine as metabolites. There is no evidence of clinically relevant drug accumulation following once daily dosing of desloratidine(5mg to 20mg ) for 14 days..

Can be taken with or without a meal.

It should not be used in pregnancy unless the potential benefits outweigh the risks. As desloratidine is excreted into breast milk, it is not recommended for use in breastfeeding women.